Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    A new platform revision label Revision: v3.5.4 was added, replacing the previous Revision: v3.5.3. This indicates a backend deployment update with no change to the page content or study details.
    Difference
    0.0%
    Check dated 2026-05-15T13:51:51.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-24T06:09:59.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:39:30.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    Revision history updated: added v3.5.0 and removed v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-19T06:13:35.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T02:23:31.000Z thumbnail image
  9. Check
    114 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added, and the prior government funding status notice (v3.4.1) was removed. The core study details and data remain unchanged.
    Difference
    0.4%
    Check dated 2026-02-11T12:22:43.000Z thumbnail image

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.